USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer’s Disease and Central Nervous System Disorders November 13, 2025 Read More »
IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025 November 10, 2025 Read More »
IGC Pharma Advances to Semi-Finals in the Alzheimer’s Insights AI Prize with “AHA: Agentic Harmonization Assistant” October 22, 2025 Read More »
IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida’s Department of Psychiatry and Behavioral Neurosciences October 14, 2025 Read More »
IGC Pharma’s Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer’s Disease October 7, 2025 Read More »
IGC Pharma Adds Ichor Research as New Site for CALMA Phase 2 Alzheimer’s Trial September 29, 2025 Read More »
IGC Pharma Announces Preclinical Data Demonstrating TGR-63’s Dual Action on Alzheimer’s Pathology September 24, 2025 Read More »
IGC Pharma Reports 50% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer’s Agitation Trial September 22, 2025 Read More »
